Find M102 manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 114873-06-2, Boc-phe(3-me)-oh, Boc-3-methy-l-phenylalanine, (s)-2-((tert-butoxycarbonyl)amino)-3-(m-tolyl)propanoic acid, Boc-d-phe(3-me)-oh, Boc-l-3-methylphenylalanine
Molecular Formula
C15H21NO4
Molecular Weight
279.33  g/mol
InChI Key
HBBXWMALJNZDOM-LBPRGKRZSA-N

M102
1 2D Structure

M102

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(2S)-3-(3-methylphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid
2.1.2 InChI
InChI=1S/C15H21NO4/c1-10-6-5-7-11(8-10)9-12(13(17)18)16-14(19)20-15(2,3)4/h5-8,12H,9H2,1-4H3,(H,16,19)(H,17,18)/t12-/m0/s1
2.1.3 InChI Key
HBBXWMALJNZDOM-LBPRGKRZSA-N
2.1.4 Canonical SMILES
CC1=CC(=CC=C1)CC(C(=O)O)NC(=O)OC(C)(C)C
2.1.5 Isomeric SMILES
CC1=CC(=CC=C1)C[C@@H](C(=O)O)NC(=O)OC(C)(C)C
2.2 Synonyms
2.2.1 Depositor-Supplied Synonyms

1. 114873-06-2

2. Boc-phe(3-me)-oh

3. Boc-3-methy-l-phenylalanine

4. (s)-2-((tert-butoxycarbonyl)amino)-3-(m-tolyl)propanoic Acid

5. Boc-d-phe(3-me)-oh

6. Boc-l-3-methylphenylalanine

7. (2s)-3-(3-methylphenyl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic Acid

8. Schembl16423

9. Boc-l-3-methyl Phenylalanine

10. Dtxsid00921524

11. L-phenylalanine, N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-

12. Zinc2386873

13. Mfcd01862944

14. Akos015836522

15. Akos015895346

16. Ac-9924

17. Am83421

18. Cs-w012282

19. As-14666

20. Boc-phe(3-me)-oh, >=98.0% (tlc)

21. 3-methyl-n-(t-butoxycarbonyl)-l-phenylalanine

22. 73m062

23. A50146

24. N-(tert-butoxycarbonyl)-3-methyl-l-phenylalanine

25. Boc-l-3-methylphenylalanine (boc-l-phe(3-me)-oh)

26. J-003145

27. (s)-2-(tert-butoxycarbonylamino)-3-m-tolylpropanoic Acid

28. N-[tert-butoxy(hydroxy)methylidene]-3-methylphenylalanine

29. (2s)-2-{[(tert-butoxy)carbonyl]amino}-3-(3-methylphenyl)propanoic Acid

2.3 Create Date
2005-07-19
3 Chemical and Physical Properties
Molecular Weight 279.33 g/mol
Molecular Formula C15H21NO4
XLogP32.5
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count6
Exact Mass279.14705815 g/mol
Monoisotopic Mass279.14705815 g/mol
Topological Polar Surface Area75.6 Ų
Heavy Atom Count20
Formal Charge0
Complexity348
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Drugs in Development

read-more
read-more

Details:

Funding supports aclipse therapeutics’ and sheffield institute of translational neuroscience’s development of M102 in amyotrophic lateral sclerosis. M102 is Aclipse’s drug candidate for the treatment of amyotrophic lateral sclerosis.


Lead Product(s): M102

Therapeutic Area: Neurology Brand Name: M102

Study Phase: PreclinicalProduct Type: Small molecule

Sponsor: Medical Research Council (U.K)

Deal Size: $2.2 million Upfront Cash: Undisclosed

Deal Type: Funding January 26, 2021

blank

01

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Lead Product(s) : M102

Therapeutic Area : Neurology

Highest Development Status : Preclinical

Partner/Sponsor/Collaborator : Medical Research Council (U.K)

Deal Size : $2.2 million

Deal Type : Funding

Details : Funding supports aclipse therapeutics’ and sheffield institute of translational neuroscience’s development of M102 in amyotrophic lateral sclerosis. M102 is Aclipse’s drug candidate for the treatment of amyotrophic lateral sclerosis.

Brand Name : M102

Molecule Type : Small molecule

Upfront Cash : Undisclosed

January 26, 2021

blank

Details:

The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease.


Lead Product(s): M102

Therapeutic Area: Neurology Brand Name: M102

Study Phase: PreclinicalProduct Type: Undisclosed

Sponsor: FightMND

Deal Size: $0.7 million Upfront Cash: Undisclosed

Deal Type: Funding September 29, 2020

blank

02

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : The grant will support the translational development of M102, a drug candidate for the treatment of amyotrophic lateral sclerosis (ALS), also known as motor neuron disease (MND) or Lou Gehrig's disease.

Brand Name : M102

Molecule Type : Undisclosed

Upfront Cash : Undisclosed

September 29, 2020

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty